When putting together your watch list, focus on stocks with an 80 or higher RS Rating. BioNTech ADR is one stock that just reached the mark, now earning a score of 81.
IBD's unique rating measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best stocks often have an 80 or higher RS Rating as they begin their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
BioNTech ADR is trying to complete a consolidation with a 131.49 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Earnings grew 29% last quarter, up from 0% in the prior report. Revenue also increased, from -25% to 46%.
BioNTech ADR earns the No. 136 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
